Eli Lilly's Q2 2026: GLP-1 Momentum Drives Revenue Beat, But Charges Cap EPS

Eli Lilly (LLY) delivered a powerful second quarter, with revenue surging 48% year over year to roughly $23 billion, powered by the continued ramp of its GLP-1 franchise. The company also raised its full-year revenue outlook, but trimmed the top end of its non-GAAP EPS guidance, reflecting a $3.03 per share charge from business development activity. The market's reaction will hinge on whether investors focus on the operational strength or the earnings drag from deal-making.

Revenue Beat Driven by Mounjaro and Zepbound

Revenue of $22.97 to $23.0 billion came in well above the consensus estimate of about $20.7 billion. The growth was led by Mounjaro, which brought in $9.94 billion, up 91% year over year, and Zepbound, which contributed $4.93 billion, a 46% increase. Combined, these two GLP-1 products accounted for roughly 65% of total revenue, underscoring Lilly's dependence on this franchise.

Volume growth was the primary driver, with total volume up about 60%, partially offset by lower realized prices. U.S. revenue grew 33%, while international revenue jumped 80%, reflecting the global rollout of these therapies. The company noted that the quarter included the first sales of its oral obesity pill, Foundayo (orforglipron), which was approved earlier in 2026, adding a new growth vector.

Margins and Profitability: Strong Underlying Performance

Gross margin expanded to 85.8%, up 1.5 percentage points year over year, reflecting manufacturing efficiencies and product mix. Reported net income rose 25% to $7.1 billion, and reported EPS came in at $7.94, up 26%. On a non-GAAP basis, EPS was $8.38, a 33% increase, easily beating consensus estimates that ranged from $6.01 to $6.58.

However, the quarter included $3.03 per share in acquired in-process research and development (IPR&D) charges, compared to just $0.14 in the year-ago period. These charges stem from business development activity, likely acquisitions or licensing deals. Excluding these charges, underlying non-GAAP EPS would have been even higher, indicating that the core business is performing exceptionally well.

Guidance: Revenue Raised, EPS Trimmed on Charges

Lilly raised its full-year 2026 revenue guidance to $85 to $87 billion, up from the prior range of $82 to $85 billion. The company also lifted its non-GAAP performance margin outlook to 49.0% to 50.5%, from 47.0% to 48.5%. However, non-GAAP EPS guidance was adjusted to $35.50 to $36.50, with the high end lowered from $37.00. The midpoint of the new EPS range is $36.00, compared to $36.25 previously.

Management explained that the underlying business performance would have supported an increase of about $2.78 per share at the midpoint, but this was more than offset by the $3.03 per share of IPR&D charges. In other words, the operational momentum is strong, but the company is choosing to invest in future growth through acquisitions, which temporarily depresses reported earnings.

Capital Allocation: Continued Manufacturing Investment

Lilly announced an additional $4.5 billion commitment to expand its Indiana manufacturing sites. This follows previous investments aimed at increasing production capacity for its GLP-1 drugs, which have faced supply constraints. The company is clearly betting on sustained demand and is building out capacity to meet it. While this capital expenditure will weigh on free cash flow in the near term, it is essential to maintain supply and defend market share against competitors like Novo Nordisk.

Pipeline and Portfolio Progress

Beyond the commercial success, Lilly highlighted progress across its pipeline in cardiometabolic, oncology, immunology, and neuroscience. The approval and launch of Foundayo (orforglipron) is a significant milestone, as it offers an oral alternative to injectable GLP-1s, potentially expanding the addressable market. The company also mentioned expanded access efforts, including Medicare GLP-1 related programs, which could drive further volume growth.

Risks and Considerations

While the quarter was strong, investors should weigh several risks. First, the reliance on GLP-1 products makes Lilly vulnerable to any setbacks in that franchise, whether from safety issues, pricing pressure, or increased competition. Second, the lower realized prices suggest that payer pressure is intensifying, which could erode margins over time. Third, the IPR&D charges indicate that Lilly is spending heavily on business development, which may not always yield successful products. Finally, the company's manufacturing expansion, while necessary, carries execution risk and could lead to oversupply if demand growth slows.

On the bullish side, the demand for obesity and diabetes treatments remains robust, and Lilly's portfolio is best-in-class. The oral formulation could open up a new patient population, and the company's manufacturing investments should help alleviate supply constraints. The raised revenue guidance and improved margin outlook suggest management's confidence in the trajectory.

Valuation and Conclusion

At current levels, Lilly trades at a premium valuation, reflecting its growth prospects. The stock is priced for continued success, and any disappointment could lead to multiple compression. However, given the strong operational performance and the potential for further upside from pipeline catalysts, the risk-reward may still be attractive for long-term investors.

In summary, Eli Lilly's Q2 2026 results demonstrate the power of its GLP-1 franchise, with revenue and underlying earnings beating expectations. The company raised its revenue guidance and improved its margin outlook, but the EPS guidance was trimmed due to acquisition-related charges. Investors should focus on the underlying strength of the business, while keeping an eye on competitive dynamics and the company's capital allocation decisions. The stock remains a core holding for those seeking exposure to the metabolic disease market, but valuation and execution risks warrant caution.